| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥576.2B | ¥759.9B | -24.2% |
| Operating Income | ¥5.5B | ¥254.2B | -97.8% |
| Ordinary Income | ¥11.7B | ¥260.8B | -95.5% |
| Net Income | ¥14.0B | ¥191.8B | -92.7% |
| ROE | 1.0% | 12.6% | - |
FY2025 Q3 cumulative results show revenue of 57.6B yen (YoY -24.2%), operating income of 5.5B yen (YoY -97.8%), ordinary income of 11.7B yen (YoY -95.5%), and net income attributable to owners of 14.0B yen (YoY -92.7%). The company experienced severe profit contraction despite maintaining product sales at near prior-year levels, primarily due to a sharp decline in license-related revenues from 19.8B yen to 1.4B yen. Operating margin deteriorated to 1.0% from 33.5% in the prior year, reflecting high fixed selling, general and administrative expenses of 30.3B yen against reduced top-line. Non-operating income contributions of 6.2B yen, including dividend income of 5.7B yen and gains on investment securities sales of 8.6B yen, partially cushioned the bottom-line impact. Total assets declined to 176.4B yen from 190.4B yen, while equity decreased to 145.8B yen from 152.6B yen. Cash and deposits contracted sharply by 31.9% to 36.8B yen, raising liquidity composition concerns despite a robust current ratio of 408.8%.
Revenue declined 24.2% YoY to 57.6B yen, driven entirely by the Medicine segment where sales fell from 74.1B yen to 55.7B yen. Within this segment, product sales remained stable at 54.4B yen (YoY +0.01%), but license contract revenues collapsed from 19.8B yen to 1.4B yen, representing a 93.2% decline. This substantial reduction in high-margin license income was the primary driver of top-line contraction. The Real Estate segment showed modest growth with sales increasing from 1.8B yen to 1.9B yen (YoY +3.9%). Operating income plummeted 97.8% from 25.4B yen to 5.5B yen, as the gross profit margin compression and unchanged SG&A burden of 30.3B yen overwhelmed profitability. The Medicine segment swung to an operating loss of 0.5B yen from a profit of 24.4B yen, while Real Estate maintained profitability at 1.0B yen. Non-operating items provided critical support, with ordinary income of 11.7B yen reflecting 7.9B yen in non-operating income, primarily from dividend income of 5.7B yen and interest income of 1.9B yen. Special profit of 8.6B yen from investment securities sales further lifted pre-tax income to 19.8B yen. After income taxes of 5.8B yen, net income reached 14.0B yen. This represents a revenue down, profit down pattern, with the profit decline substantially exceeding the revenue decline due to operational deleverage and loss of high-margin license revenues.
The Medicine segment is the core business, accounting for 96.7% of total revenue at 55.7B yen. However, this segment incurred an operating loss of 0.5B yen in the current period, a sharp deterioration from a profit of 24.4B yen in the prior year. The primary factor was the 93.2% decline in license contract revenues from 19.8B yen to 1.4B yen, eliminating a highly profitable revenue stream while product sales of 54.4B yen remained essentially flat. The segment's operating margin collapsed to negative 0.9% from positive 32.9%, indicating severe profitability pressure due to fixed cost absorption challenges. The Real Estate segment contributed 1.9B yen in revenue (3.3% of total) and maintained operating income of 1.0B yen, representing an operating margin of 54.1%, substantially above the company average. Despite representing a small revenue share, Real Estate's stable profitability provided critical offset to the Medicine segment's losses, contributing 187% of consolidated operating income due to the latter's loss position.
[Profitability] ROE of 1.0% declined sharply from the prior year, with operating margin compressed to 1.0% from 33.5% YoY, reflecting severe operational deleverage. Net profit margin of 2.4% similarly contracted from 25.2% as SG&A expenses remained elevated at 30.3B yen against reduced revenue. ROIC deteriorated to 0.3% from 16.6%, indicating very weak returns on deployed capital. [Cash Quality] Cash and equivalents of 36.8B yen provide 9.6x coverage of short-term debt of 3.9B yen, indicating adequate near-term liquidity despite the 31.9% YoY cash decline. [Investment Efficiency] Total asset turnover of 0.33x reflects moderate asset utilization. Working capital efficiency metrics show significant deterioration with DSO at 153 days, DIO at 281 days, and cash conversion cycle extended to 299 days, all indicating substantial operational inefficiencies in receivables collection and inventory management. [Financial Health] Equity ratio of 82.6% remains robust, up from 80.1% YoY, reflecting a conservative capital structure. Current ratio of 408.8% and quick ratio of 372.3% indicate strong short-term solvency, though debt-to-equity of 0.026 and debt-to-capital of 2.6% confirm minimal leverage. Interest-bearing liabilities total 3.9B yen, all classified as short-term borrowings. [Pharma-Specific] R&D expenses of 15.6B yen represent substantial ongoing investment, though R&D intensity as a percentage of revenue rose to 27.2% due to revenue contraction rather than increased R&D spending.
Cash and deposits decreased 17.2B yen YoY to 36.8B yen, representing a 31.9% decline that signals material cash consumption during the period. Working capital movements reveal operational cash pressures, with trade receivables increasing 0.5B yen to 24.1B yen while inventories rose 4.6B yen to 44.2B yen, indicating inventory accumulation and slower turnover. Trade payables decreased 3.7B yen to 12.8B yen, suggesting reduced supplier credit utilization and potential payment acceleration. The combination of rising receivables and inventories alongside declining payables indicates significant operating working capital outflow. Interest-bearing liabilities remained stable at 3.9B yen, all in short-term form, while cash coverage of short-term debt stands at 9.6x, providing adequate liquidity buffer despite the cash decline. The substantial reduction in cash holdings alongside working capital deterioration and high dividend payments suggests cash generation challenges, with non-operating sources such as dividend income of 5.7B yen and investment securities sales proceeds partially offsetting operational outflows.
Ordinary income of 11.7B yen versus operating income of 5.5B yen reflects a non-operating net contribution of approximately 6.2B yen, comprising primarily equity method gains, financial income, and dividend income. Non-operating income of 7.9B yen represents 13.7% of revenue and consists of dividend income of 5.7B yen and interest income of 1.9B yen as primary components, indicating material dependence on non-operating sources for profitability. Special profit of 8.6B yen from investment securities sales represents a non-recurring gain that elevated pre-tax income to 19.8B yen. The operating income base of 5.5B yen therefore reflects core recurring profitability, which is severely depressed. The substantial gap between operating income and net income indicates that earnings quality is compromised by reliance on non-operating and non-recurring items rather than sustainable operational performance. Working capital metrics with DSO at 153 days and DIO at 281 days suggest potential accruals buildup in receivables and inventory that may not convert efficiently to cash, further indicating earnings quality concerns from an operational cash generation perspective.
Full-year guidance anticipates revenue of 86.3B yen, operating income of 2.1B yen, ordinary income of 2.8B yen, and net income of 2.3B yen, with annual dividend of 95 yen per share. As of Q3 cumulative (9 months), revenue progress stands at 66.8% of full-year guidance, lagging the standard 75% benchmark by 8.2 percentage points. Operating income progress of 263.8% significantly exceeds guidance, appearing anomalous due to the extremely low full-year operating income forecast of 2.1B yen; the Q3 cumulative actual of 5.5B yen suggests either conservative guidance or anticipated Q4 deterioration. Ordinary income progress of 417.9% and net income progress of 607.8% similarly exceed full-year expectations, driven by non-recurring gains in Q1-Q3 that may not recur in Q4. The company has maintained unchanged full-year guidance despite substantial Q3 progress divergence, implying expectations of significant Q4 headwinds or one-time Q1-Q3 gains not expected to continue. Revenue shortfall against typical progress pace indicates delivery risk, while profit over-delivery stems from non-recurring factors. Investors should note the guidance assumes YoY revenue decline of 8.2%, operating income decline of 90.0%, and ordinary income decline of 86.8% for the full year.
The company paid an interim dividend of 115 yen per share in Q2 and forecasts a year-end dividend of 75 yen per share, totaling 190 yen annually compared to the full-year guidance of 95 yen per share. Based on Q3 cumulative net income of 14.0B yen and shares outstanding of 44.14 million, the calculated payout ratio for the interim and forecast year-end dividends reaches approximately 600%, far exceeding sustainable levels. This extraordinarily high payout ratio indicates the dividend is being funded from accumulated retained earnings or asset liquidations rather than current period profits, raising sustainability concerns. The full-year guidance dividend of 95 yen against forecast net income of 2.3B yen implies a payout ratio of approximately 182%, still well above the sustainable 100% threshold. No share buyback activity is disclosed in the available data. The dividend policy appears to prioritize shareholder returns despite severely compressed earnings, but the current profit level cannot support the historical dividend level without drawing on reserves.
Revenue concentration risk in the Medicine segment at 96.7% of sales, with heavy dependence on license contract revenues that collapsed 93.2% YoY from 19.8B yen to 1.4B yen, creates significant earnings volatility. The prior year's license revenues represented approximately 26% of Medicine segment sales, and their near-total disappearance eliminated the segment's profitability. Recurrence or sustainability of such revenues remains highly uncertain. Working capital management deterioration poses operational cash flow risk, with DSO extended to 153 days (vs. industry median of 152 days), DIO at 281 days (matching industry median of 282 days), and cash conversion cycle of 299 days, indicating 299 days from cash outlay to cash collection. These extended cycles tie up substantial capital and reduce financial flexibility. Dividend sustainability risk is acute, with the calculated payout ratio of 600% based on Q3 results and 182% based on full-year guidance both indicating that dividends substantially exceed earnings. Cash and deposits declined 31.9% to 36.8B yen while dividends consume profits, suggesting reliance on balance sheet strength that cannot continue indefinitely without profit recovery.
[Industry Position] (Reference - Proprietary Analysis)
Profitability: ROE of 1.0% substantially exceeds the pharmaceutical industry median of -35.8% (IQR: -91.4% to -6.1%), positioning the company favorably within a sector experiencing widespread losses. Operating margin of 1.0% also exceeds the industry median of -218.2% (IQR: -628.8% to -14.9%), though this reflects industry-wide distress rather than strong company performance. ROIC of 0.3% similarly outperforms the industry median of -0.32 (IQR: -1.45 to -0.02). Financial Health: Equity ratio of 82.6% is substantially higher than the industry median of 67.8% (IQR: 62.1% to 79.1%), indicating superior financial stability and a conservative capital structure. Current ratio of 408.8% significantly exceeds the industry median of 6.62x, though direct comparison is complicated by the differing magnitude scale. Efficiency: Asset turnover of 0.33x is nearly double the industry median of 0.17 (IQR: 0.05 to 0.24), indicating relatively efficient asset utilization. However, receivables turnover at 153 days aligns closely with industry median of 152 days, while inventory turnover of 281 days matches the industry median of 282 days, suggesting typical operational efficiency for the sector. Cash conversion cycle of 299 days suggests working capital efficiency challenges that are sector-typical. Growth: Revenue decline of 24.2% YoY underperforms the industry median decline of 12.5% (IQR: -22.1% to -2.5%), placing the company in the lower quartile for revenue performance. The company demonstrates relative resilience in profitability metrics versus industry peers but faces above-average top-line contraction pressure.
(Industry: Pharmaceutical, N=13 companies, Comparison: 2025-Q3, Source: Proprietary analysis)
The Q3 cumulative results reveal a company navigating severe operational challenges stemming from a 93% collapse in high-margin license revenues that previously contributed approximately one-quarter of Medicine segment sales and drove segment profitability. Core product sales of 54.4B yen remained stable, but the fixed SG&A expense base of 30.3B yen cannot be absorbed at reduced revenue levels, compressing operating margin to 1.0%. The company's reliance on non-operating income sources including 5.7B yen in dividends and 8.6B yen in investment securities sale gains to generate net income of 14.0B yen indicates that operational earnings power is severely impaired, with core operating income of only 5.5B yen insufficient to sustain historical dividend levels. The 31.9% decline in cash holdings to 36.8B yen alongside working capital deterioration metrics—DSO at 153 days, DIO at 281 days, and cash conversion cycle of 299 days—signals operational cash generation stress that requires urgent working capital management improvement. Despite these pressures, the company maintains exceptional financial stability with an equity ratio of 82.6%, minimal leverage at 2.6% debt-to-capital, and current ratio of 408.8%, providing substantial balance sheet capacity to weather the downturn. The divergence between Q3 cumulative profit achievement exceeding full-year guidance (operating income 264% of guidance, net income 608% of guidance) versus revenue shortfall (67% of guidance) suggests Q1-Q3 benefited from non-recurring gains unlikely to continue, with Q4 potentially facing significant headwinds. Full-year guidance implies management expects material Q4 deterioration, maintaining conservative profit forecasts despite strong Q3 cumulative results. The pharmaceutical industry context of widespread losses (median ROE of -35.8%, median operating margin of -218.2%) positions the company's positive profitability favorably in relative terms, though absolute performance remains weak. Key forward-looking factors include the pipeline of R&D investments at 15.6B yen delivering future product launches or license revenues to restore top-line growth, working capital efficiency improvements to enhance cash generation, and SG&A cost management to restore operating leverage as revenues stabilize.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.